Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 May;33(5):53.
doi: 10.1007/s12032-016-0767-3. Epub 2016 Apr 20.

Inhibition of glioblastoma cell proliferation, migration and invasion by the proteasome antagonist carfilzomib

Zammam Areeb  1 , Stanley S Stylli  1   2 , Thomas M B Ware  1 , Nicole C Harris  3   4 , Lipi Shukla  3   4 , Ramin Shayan  3   4 , Lucia Paradiso  1 , Bo Li  5   6 , Andrew P Morokoff  1   2 , Andrew H Kaye  1   2 , Rodney B Luwor  7
Affiliations

Inhibition of glioblastoma cell proliferation, migration and invasion by the proteasome antagonist carfilzomib

Zammam Areeb et al. Med Oncol. 2016 May.

Abstract

Glioblastoma multiforme is the most aggressive and lethal tumor of the central nervous system with limited treatment strategies on offer, and as such the identification of effective novel therapeutic agents is paramount. To examine the efficacy of proteasome inhibitors, we tested bortezomib, carfilzomib, nafamostat mesylate, gabexate mesylate and acetylsalicylic acid on glioblastoma cell viability, migration and invasion. Both bortezomib and carfilzomib produced significant reduction of cell viability, while nafamostat mesylate, gabexate mesylate and acetylsalicylic acid did not. Subsequent testing showed that carfilzomib significantly reduced cell viability at nM concentrations. Carfilzomib also reduced cell migration, secretion and activation of MMP2 and also cell invasion of all four glioblastoma cells tested. In summary, carfilzomib represents a novel, yet FDA-approved agent for the treatment of glioblastoma multiforme.

Keywords: Carfilzomib; Glioblastoma multiforme; Invasion; MMP2; Migration; Proteasome.

PubMed Disclaimer

References

    1. Lancet Oncol. 2009 May;10 (5):459-66 - PubMed
    1. Mol Cancer Res. 2008 Mar;6(3):426-34 - PubMed
    1. Curr Oncol. 2014 Aug;21(4):e573-603 - PubMed
    1. Oncogene. 2008 Sep 18;27(41):5416-30 - PubMed
    1. Cell Tissue Res. 2015 Oct;362(1):45-60 - PubMed

MeSH terms

LinkOut - more resources